PUBLIC COMPANY
save$RCUSArcus Biosciences, Inc.
$RCUS29.52-2.73%Hayward, CA, USupdated 8h ago
community read0 votes
pipeline
3
marketed
0
phase 3
1
catalysts ytd
4
approvals ytd
0
recalls ytd
0
Pipeline(3)
pipeline depth3 products
1Phase 11Phase 21Phase 3
Upcoming
Recent(90d)
earnings (1)
Active trials
- phase3Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma
- phase1A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors
- phase2A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper Gastrointestinal Tract Malignancies
- phase3Study of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
- phase1A Study of AB801 Monotherapy and Combination Therapy in Participants With Advanced Malignancies
- phase1A Bioequivalence Study Between Two Casdatifan Tablet Strengths and Food Effect Study of Casdatifan in Healthy Adult Participants
- phase1Metabolism, Excretion, and Mass Balance Study of Quemliclustat in Healthy Adult Participants (ARC-24)
- phase2Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer
🐶 Hiring Signal
next earnings Oct 27, 2026
News
- AstraZeneca has no plans to ramp up dealmaking in wake of Wainua failureAstraZeneca remains "very much on track" to hit its 2030 goal of reaching $80 billion in revenue despite the recent late-stage failure of Wainua in ATTR-cardiomyopathy, CEO Pascal Soriot said durin…biospace · 24d ago
Data sources
last refreshed 18m ago
Found something off?
comments(0)
5-min edit window · permanent after that